The inhibition effect of natural food supplement active ingredients on TP63 carcinoma cell

Cancer shared this article with you from Inoreader The inhibition effect of natural food supplement active ingredients on TP63 carcinoma cell Via Latest Results for Medical Oncology Abstract In pancreatic cancer, the activities of inhibitory agents were investigated using docking, since the inhibition of TP63, which plays an important role in the spread of cancer with metastasis, in preventing the proliferation and proliferation of this type of cancer. It has been shown that the active ingredients in some plants used as traditional medicines have an inhibitory effect on this cancer type in preventing growth, reproduction and spread. These computational results guide experimental studies, preventing time and item loss; It is an important study in terms of choosing and using the right active substances. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Prognostic Value of Soluble Programmed Cell Death Ligand-1 (sPD-L1) in Various Cancers: A Meta-analysis

Cancer shared this article with you from Inoreader Prognostic Value of Soluble Programmed Cell Death Ligand-1 (sPD-L1) in Various Cancers: A Meta-analysis Via Latest Results for Targeted Oncology Abstract Background The prognostic value of soluble programmed cell death ligand-1 (sPD-L1) in patients with cancer has been inconsistent across previous studies. Objective This meta-analysis aimed to investigate the prognostic significance of sPD-L1 in human tumors. Methods A comprehensive search of PubMed, Web of Science, Embase, and Cochrane databases from inception to January 6, 2020 was conducted. Studies of sPD-L1 measured by enzyme-linked immunosorbent assay (ELISA) that had available hazard ratios (HRs) for survival outcomes based on high or low sPD-L1 levels were included. The primary endpoint was long-term survival, namely, overall survival (OS), and the second endpoint was short-term survival, including progression-free survival (PFS), disease-free survival (DFS), recurrence-free survival (RFS), and cancer-specific survival (CSS). Results A total of 21 studies, with 2413 patients, were included in this meta-analysis. Elevated sPD-L1 was associated with worse OS [HR = 2.46, 95% confidence interval (CI) 1.74–3.49, P < 0.001]. Moreover, high sPD-L1 was predictive of worse PFS/DFS/RFS/CSS (HR = 2.22, 95% CI 1.47–3.35, P < 0.001). High sPD-L1 was consistently correlated with poor OS and PFS/DFS/RFS/CSS irrespective of study design, sample, and cut-off value of sPD-L1. However, there was non-significant correlation between sPD-L1 and sex, age, clinical stage, Eastern Cooperative Oncology Group Performance Status, tumor differentiation, or serum lactate dehydrogenase. Conclusions This meta-analysis showed that sPD-L1 was correlated with poor prognosis in human tumors. In addition, sPD-L1 could be used as a predictive factor of inferior outcomes during multiple malignancy treatments. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

microRNA-211-mediated targeting of the INHBA-TGF-β axis suppresses prostate tumor formation and growth

Cancer shared this article with you from Inoreader microRNA-211-mediated targeting of the INHBA-TGF-β axis suppresses prostate tumor formation and growth Via Cancer Gene Therapy - Issue - nature.com science feeds Cancer Gene Therapy, Published online: 22 November 2020; doi:10.1038/s41417-020-00237-w microRNA-211-mediated targeting of the INHBA-TGF-β axis suppresses prostate tumor formation and growth View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Dose Fractionation During Puberty is More Detrimental to Mammary Gland Development Than an Equivalent Acute Dose of Radiation Exposure

Cancer shared this article with you from Inoreader Dose Fractionation During Puberty is More Detrimental to Mammary Gland Development Than an Equivalent Acute Dose of Radiation Exposure Via ScienceDirect Publication: International Journal of Radiation Oncology*Biology*Physics Publication date: Available online 21 November 2020 Source: International Journal of Radiation Oncology*Biology*Physics Author(s): Brandi Wiedmeyer, Jennifer To, Deepa.M. Sridharan, Lung-Chang Chien, Antoine M. Snijders, Hidetoshi Mori, Janice Pluth View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Isotoxic Intensity Modulated Radiotherapy in stage III NSCLC – A feasibility study

Cancer shared this article with you from Inoreader Isotoxic Intensity Modulated Radiotherapy in stage III NSCLC – A feasibility study Via ScienceDirect Publication: International Journal of Radiation Oncology*Biology*Physics Publication date: Available online 21 November 2020 Source: International Journal of Radiation Oncology*Biology*Physics Author(s): Kate Haslett, Neil Bayman, Kevin Franks, Nicki Groom, Susan V. Harden, Catherine Harris, Gerard Hanna, Stephen Harrow, Matthew Hatton, Paula McCloskey, Fiona McDonald, W. David Ryder, Corinne Faivre-Finn View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Polymorphonuclear-MDSCs facilitate tumor regrowth after radiation by suppressing CD8+ T cells

Cancer shared this article with you from Inoreader Polymorphonuclear-MDSCs facilitate tumor regrowth after radiation by suppressing CD8<sup>+</sup> T cells Via ScienceDirect Publication: International Journal of Radiation Oncology*Biology*Physics Publication date: Available online 22 November 2020 Source: International Journal of Radiation Oncology*Biology*Physics Author(s): Jieying Zhang, Liling Zhang, Yuhui Yang, Qing Liu, Hong Ma, Ai Huang, Yanxia Zhao, Zihan Xia, Tao Liu, Gang Wu View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

The quality of reporting general safety parameters and immune-related adverse events in clinical trials of FDA-approved immune checkpoint inhibitors

Cancer shared this article with you from Inoreader The quality of reporting general safety parameters and immune-related adverse events in clinical trials of FDA-approved immune checkpoint inhibitors Via Latest Results for BMC Cancer Abstract Background While immune-checkpoint inhibitors (ICIs) have transformed the field of oncology for advanced-stage cancers, they can lead to serious immune toxicities. Several systematic reviews have evaluated the risk of immune-related adverse events (irAEs); however, most have focused on published articles without evaluating trial registries. The objective of this methodological review was to compare the quality of reporting of safety information and in particular, serious irAEs (irSAEs), in both publications and ClinicalTrials.gov for all current FDA-approved ICIs. Methods PubMed was searched to retrieve all published phase III randomized controlled trials (RCTs) evaluating ICIs. For each eligible trial, we searched for corresponding registration on ClinicalTrials.gov and extracted relevant safety data from both the publication and results posted on registry. We then compared the quality of reporting and the value of safety data between both sources. Results Of 42 eligible published trials, 34 had results posted on ClinicalTrials.gov. Considerable variability was noted in the reporting of safety in both sources. SAEs were reported for all trial results in ClinicalTrials.gov compared to 23.5% of publications. An overall incidence for irAEs and irSAEs was reported in 58.8 and 8.8% of publications respectively, compared to 11.8 and 5.9% in registry results. Comparing the value of specific irSAEs was not possible between the two sources in 32/34 trials either due to different reporting formats (61.8%) or data not being reported in one or both sources (32.4%). From the 2 studies with compatible irSAE format, only 1 had matching data in both sources. Conclusions The reporting of irAEs / irSAEs varies considerably in publications and registries, which outlines the importance of standardizing the terminologies and methodologies for reporting safety information relevant to ICIs. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Modification of the 8th American Joint Committee on Cancer staging system for gallbladder carcinoma to improve prognostic precision

Cancer shared this article with you from Inoreader Modification of the 8th American Joint Committee on Cancer staging system for gallbladder carcinoma to improve prognostic precision Via Latest Results for BMC Cancer Abstract Background The 8th edition of the American Joint Committee on Cancer (AJCC) staging system for gallbladder carcinoma (GBC) came into force since 2018. However, the prognostic precision of this staging system has not been properly assessed. This study aimed to evaluate the latest staging system and suggest modifications to improve its prognostic precision. Methods Data of patients with GBC was included from the Surveillance, Epidemiology and End Results (SEER) database (2004–2015) and multicenter database (2010–2017). Baseline clinicopathologic characteristics were recorded including age, sex, race, grade, T category, N category, M category and stage. The Kaplan-Meier method was used to plot survival functions. The prediction power of the AJCC 8th edition and its modified version were evaluated using the concordance index (C-index). Results A total of 2779 GBC patients were included in the SEER database and 591 were collected from multicenter database. While no significant difference in survival of patients was observed between stages IVA and IVB using the 8th AJCC staging system (p > 0.05), the prognosis of stage IIIA showed a slightly better outcome than stage IIIB (p = 0.046) in the SEER database. In the multicenter database, there was no significant difference between stage IIIA and stage IIIB (p > 0.05). Similarly, no significant difference in the survival of patients between stages IIIA and IIIB was observed when M0 patients with at least 6 lymph nodes (LNs) were analyzed (p > 0.05) for both SEER and multicenter database. On the other hand, a modified staging system was able to stratify patients from stage IIIA, stage IIIB and stage IV (p < 0.001). For the SEER database, the C-indexes of 8th AJCC staging system an d that of its modified version were 0.709 and 0.742, respectively. For the multicenter database, the C-index of 8th AJCC staging system and that of our modified version were 0.635 and 0.679, respectively. Conclusions The modified 8th staging system proposed in this study can improve the prognostic precision of the 8th AJCC staging system for GBC. We therefore suggest including these modifications in the next update of AJCC staging system for GBC. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Interferon-lambda ( IFNL ) germline variations and their significance for HCC and PDAC progression: an analysis of The Cancer Genome Atlas (TCGA) data

Cancer shared this article with you from Inoreader Interferon-lambda ( IFNL ) germline variations and their significance for HCC and PDAC progression: an analysis of The Cancer Genome Atlas (TCGA) data Via Latest Results for BMC Cancer Abstract Background Hepatocellular carcinoma (HCC) and pancreatic ductal adenocarcinoma (PDAC) are malignancies with a leading lethality. With reference to interferons (IFNs) known to mediate antitumor activities, this study investigated the relationship between germline genetic variations in type III IFN genes and cancer disease progression from The Cancer Genome Atlas (TCGA) data. The genetic variations under study tag a gain-or-loss-of-function dinucleotide polymorphism within the IFNL4 gene, rs368234815 [TT/ΔG]. Methods The entirety of the TCGA sequencing data was used to assess genotypes of 187 patients with HCC and of 162 patients with PDAC matched for ethnicity. Stratified for IFNL genotypes, both cohorts were subjected to time-to-event analyses according to Kaplan-Meier with regard to the length of the specific progression free interval (PFI) and the overall survival (OS) time as two clinical endpoints for disease progression. Results Logrank analysis revealed a significant relationship between IFNL genotypes and disease outcome for PDAC. This relationship was not found for HCC. A multiple Cox regression analysis employing patients' age, tumor grade and tumor stage as further covariates proved IFNL genotypes to be independent predictors for PDAC disease outcome. Conclusion This repository-based approach unveiled clinical evidence suggestive for an impact of IFNL germline variations for PDAC progression with an IFNL haplotype predisposing for IFNL4 expression being favorable. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Hepatocellular carcinoma: Intratumoral EpCAM-positive cancer stem cell heterogeneity identifies high-risk tumor subtype

Cancer shared this article with you from Inoreader Hepatocellular carcinoma: Intratumoral EpCAM-positive cancer stem cell heterogeneity identifies high-risk tumor subtype Via Latest Results for BMC Cancer Abstract Background The translational interest in the intratumoral heterogeneity of hepatocellular carcinoma (HCC) has been increasing. The dismal prognosis of this pathology is linked to the features of the HCC harbouring cancer stem cells (CSC), represented by EpCAM-expression. However, the extent of the impact of intratumoral distribution of CSC-features, both on the recurrence after curative resection and on clinical outcome, remains unknown. To address this, we investigated the spatial heterogeneity of CSC-features with the aim of identifying the unique HCC patient subgroups amenable to adjuvant treatment. Methods We designed a tissue microarray (TMA) from patients who had received liver resection between 2011 and 2017. Tumor specimens were sampled at multiple locations (n = 3–8). EpCAM-positivity was assessed for intensity and proportion by applying a score dividing three groups: (i) negative (E−/−); (ii) heterogeneous (E−/+); and (iii) homogeneous (E+/+). The groups were further analysed with regard to time-to-recurrence (TTR) and recurrence-free-survival (RFS). Results We included 314 tumor spots from 69 patients (76.8% male, median age 66, liver cirrhosis/fibrosis 75.8%). The risk factors were alcohol abuse (26.2%), NASH (13.1%), HBV (15.5%), HCV (17.9%) and others (27.4%), representative of a typical Western cohort. E+/+ patients experienced significantly shorter TTR and RFS compared to E+/− and E−/− patients (TTR 5 vs. 19 months, p = 0.022; RFS 5 vs. 14 vs. 21 months, p = 0.016). Only homogeneous EpCAM-positivity correlated with higher AFP levels (> 400 ng/ml, p = 0.031). Conclusions Spatial heterogeneity of EpCAM-expression was markedly present in the cohort. Of note, only homogeneous EpCAM-expression correlated significantly with early recurrence, whereas heterogeneous EpCAM-expression was associated with clinical endpoints comparable to EpCAM-negativity. We identified a unique HCC subtype associated with a high risk of tumor recurrence. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Phase 1 Trial of LVGN7409 (CD40 Agonist Antibody) as Single Agent and Combination Therapies in Advanced or Metastatic Malignancy

Cancer shared this article with you from Inoreader Phase 1 Trial of LVGN7409 (CD40 Agonist Antibody) as Single Agent and Combination Therapies in Advanced or Metastatic Malignancy Via MedWorm Cancer & Oncology Clinical Trials Condition:   Cancer Intervention:   Biological: LVGN7409 Sponsor:   Lyvgen Biopharma Holdings Limited Not yet recruiting (Source: ClinicalTrials.gov) View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Camrelizumab Combined With Chemotherapy for Recurrent or Advanced Cervical Neuroendocrine Carcinomas

Cancer shared this article with you from Inoreader Camrelizumab Combined With Chemotherapy for Recurrent or Advanced Cervical Neuroendocrine Carcinomas Via MedWorm Cancer & Oncology Clinical Trials Conditions:   Chemotherapy;   Anti-pd-1 Antibody;   Cervical Neuroendocrine Carcinoma;   Adverse Drug Event;   Recurrent Cervical Carcinoma;   Advanced Cervical Carcinoma;   Objective Response Rate Intervention:   Drug: Drug therapy Sponsor:   Lei Li Recruiting (Source: ClinicalTrials.gov) View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.